| 203.66 0.5 (0.25%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 238.82 | 1-year : | 278.94 |
| Resists | First : | 204.47 | Second : | 238.82 |
| Pivot price | 195.5  |
|||
| Supports | First : | 175.43 |
Second : | 157.49 |
| MAs | MA(5) : | 201.95 |
MA(20) : | 191.51 |
| MA(100) : | 170.86 |
MA(250) : | 0 | |
| MACD | MACD : | 7.1 |
Signal : | 6.2 |
| %K %D | K(14,3) : | 95.3 |
D(3) : | 94.2 |
| RSI | RSI(14): 71.3 |
|||
| 52-week | High : | 204.47 | Low : | 91.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRL ] has closed below upper band by 16.1%. Bollinger Bands are 15.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 204.44 - 205.2 | 205.2 - 205.81 |
| Low: | 200.25 - 201.22 | 201.22 - 202 |
| Close: | 202.21 - 203.7 | 203.7 - 204.9 |
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Wed, 24 Dec 2025
Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Tue, 23 Dec 2025
Charles River Laboratories International (NYSE:CRL) Shares Gap Up - Here's What Happened - MarketBeat
Tue, 23 Dec 2025
Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL) - FinancialContent
Tue, 23 Dec 2025
Charles River Laboratories (CRL): Valuation Check After SEC Clearance and BofA Upgrade Lift the Stock - simplywall.st
Mon, 22 Dec 2025
Is Charles River Laboratories stock underperforming the Dow? - MSN
Mon, 22 Dec 2025
Why Charles River Laboratories (CRL) Stock Is Trading Up Today - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 49 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 2,570 (K) |
| Shares Short P.Month | 2,430 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 69.19 |
| Profit Margin | -2.1 % |
| Operating Margin | 15 % |
| Return on Assets (ttm) | 4.3 % |
| Return on Equity (ttm) | -2.2 % |
| Qtrly Rev. Growth | -0.5 % |
| Gross Profit (p.s.) | 28.44 |
| Sales Per Share | 81.67 |
| EBITDA (p.s.) | 17.97 |
| Qtrly Earnings Growth | -17.3 % |
| Operating Cash Flow | 749 (M) |
| Levered Free Cash Flow | 548 (M) |
| PE Ratio | -133.99 |
| PEG Ratio | 0 |
| Price to Book value | 2.94 |
| Price to Sales | 2.49 |
| Price to Cash Flow | 13.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|